In addition, GRHL2 promoted the apoptotic effects of HDAC inhibitors, which is consistent with previous reports that reverting the mesenchymal state of GBM may promote therapeutic sensitivity [36,45]. This evidence concerns the gene HDAC9 and glioblastoma.